Search in:

Leukemia & Lymphoma Volume 61, 2020 - Issue 9

Submit an article Journal homepage

291

Views

CrossRef citations to date

Altmetric

Original Articles

A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy

Anna AsklidDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Correspondence[email protected]
View further author information

Sandra Eketorp SylvanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; View further author information

Agnes MattssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Internal Medicine, Stockholm, Sweden; View further author information

Maria WinqvistDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital, Stockholm, SwedenView further author information

Hemming JohanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; View further author information

Anders ÖsterborgDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital, Stockholm, SwedenView further author information

Lotta HanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital, Stockholm, SwedenView further author information

show all

Pages 2136-2144 | Received 24 Jan 2020, Accepted 28 Apr 2020, Published online: 25 May 2020

Cite this article
https://doi.org/10.1080/10428194.2020.1765233
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions

References

Regionala Cancercentrum i samverkan. Nationellt kvalitetsregister lymfom; Årsrapport från Nationella kvalitetsregistret för lymfom, diagnosperioden 2000-2017. Available from: https://wwwcancercentrumse/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/kvalitetsregister/
Google Scholar
Regionalt Cancercentrum i samverkan. Nationellt vårdprogram Aggressiva B-cellslymfom. 2018-02-27 Version: 3.0. Available from: https://wwwcancercentrumse/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/vardprogram/gallande-vardprogram-aggressiva-b-cellslymfom/
Google Scholar
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
PubMed Web of Science ®Google Scholar
Ekberg S, Jerkeman M, Andersson PO, et al. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. Am J Hematol. 2018;93(8):1020–1028.
Web of Science ®Google Scholar
Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013;19(7):1660–1669.
PubMed Web of Science ®Google Scholar
Peyrade F, Jardin F, Thieblemont C, et al.; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468.
PubMed Web of Science ®Google Scholar
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
PubMed Web of Science ®Google Scholar
Chihara D, Westin JR, Oki Y, et al. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016;122(20):3145–3151.
PubMed Web of Science ®Google Scholar
Aoki K, Takahashi T, Tabata S, et al. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54(11):2441–2447.
PubMed Web of Science ®Google Scholar
Iioka F, Izumi K, Kamoda Y, et al. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. Int J Clin Oncol. 2016;21(3):498–505.
PubMed Web of Science ®Google Scholar
Sylvan SE, Asklid A, Johansson H, et al. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 2019;104(4):797–804.
PubMed Web of Science ®Google Scholar
The World Medical Association. 64th WMA General Assembly Fortaleza Brazil, October 2013. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects 2018. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
Google Scholar
Parmelee PA, Thuras PD, Katz IR, et al. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130–137.
PubMed Web of Science ®Google Scholar
Cheson BD, Pfistner B, Juweid ME, et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
PubMed Web of Science ®Google Scholar
Hasselblom S, Stenson M, Werlenius O, et al. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma. 2012;53(3):394–399.
PubMed Web of Science ®Google Scholar
Williams JN, Rai A, Lipscomb J, et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121(11):1800–1808.
PubMed Web of Science ®Google Scholar
Gobba S, Moccia AA, Gulden-Sala W, et al. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: a large retrospective study from 4 institutions. Hematol Oncol. 2018;36(1):84–92.
PubMed Web of Science ®Google Scholar
Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma. 2014;55(3):526–532.
PubMed Web of Science ®Google Scholar
Kontis V, Bennett JE, Mathers CD, et al. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389(10076):1323–1335.
PubMed Web of Science ®Google Scholar
Arias E, Jiaquan X. United States life tables. National Vital Statistics Reports (NVSS). 2019;68(7):1–66. https://www.cdc.gov/nchs/products/index.htm
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date